Age 18 years and above Diagnosis of relapsing or refractory EGPA at least 6 months previously and had been taking stable dose of prednisolone or prednisone (≥7.5 to ≤50.0 mg per day, with or without additional immunosuppressive therapy) for at least 4 weeks before the baseline visit
Granulomatosis with polyangiitis or microscopic polyangiitis Organ-threatening or life-threatening eosinophilic granulomatosis with polyangiitis within 3 months before screening
Accrued weeks of remission over a 52-week period Proportion of participants in remission at both week 36 and week 48
A diagnosis of CSS as defined by the American College of Rheumatology classification criteria. Patient to be maintained on a stable dose of at least 10 mg of prednisone daily (or equivalent) before enrollment. Subjects receiving adjunct therapies, such as cyclophosphamide, azathioprine, or methotrexate, were required to maintain a stable dose so that medication withdrawal would not obfuscate potential drug benefits.
Patients with non-CSS hypereosinophilic syndromes, Wegener granulomatosis, malignancy, or parasitic disease. Pregnant or nursing female patients. Female subjects with child-bearing potential.
Whether mepolizumab safely decreased CSS disease activity and permitted scheduled tapering of systemic Corticosteroids. Lowest prednisone dose achieved at the end of the treatment phase
Patients with active refractory or relapsing active Churg–Strauss syndrome, defined by a Birmingham Vasculitis Activity Score (BVAS) greater than 3 despite treatment with immunosuppressants plus glucocorticoids at a dosage of 12.5 mg/d or higher.
NA
Remission at week 32, as defined by recommendations from the European League Against Rheumatism of a BVAS of 0 and a glucocorticoid dosage of less than 7.5 mg/d.
750 mg i.v. infusion every 4 weeks
Remission was defined as Birmingham Vasculitis Activity Score (BVAS) of zero and the receipt of prednisolone or prednisone at a dose of 4 mg or less per day over the 52-week period.
